US5185319A - Stabilization of organic compounds - Google Patents

Stabilization of organic compounds Download PDF

Info

Publication number
US5185319A
US5185319A US07/520,203 US52020390A US5185319A US 5185319 A US5185319 A US 5185319A US 52020390 A US52020390 A US 52020390A US 5185319 A US5185319 A US 5185319A
Authority
US
United States
Prior art keywords
hydroxy
aliphatic
methylpyrid
hydroxypyrid
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/520,203
Other languages
English (en)
Inventor
Robert C. Hider
Michael A. Stockham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Assigned to NATIONAL RESEARCH DEVELOPMENT CORPORATION, A BRITISH CORP. reassignment NATIONAL RESEARCH DEVELOPMENT CORPORATION, A BRITISH CORP. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: HIDER, ROBERT C., STOCKHAM, MICHAEL A.
Assigned to BRITISH TECHNOLOGY GROUP LIMITED reassignment BRITISH TECHNOLOGY GROUP LIMITED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: NATIONAL RESEARCH DEVELOPMENT CORPORATION
Application granted granted Critical
Publication of US5185319A publication Critical patent/US5185319A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • This invention relates to the stabilization of organic compounds, in particular of peptides and proteins.
  • Peptides and proteins can show instability with cleavage occurring at ##STR1## bonds therein to form smaller molecules.
  • Different theories have been advanced as to which amino acid residues are particularly likely to lead to instability, one of these identifying histidine and proline residues.
  • Considerable problems can arise in the manufacture and storage of such compounds as a consequence of their lack of stability which can be illustrated by reference to one of the commonest of the various peptides and proteins used in therapy, insulin, which is used for the treatment of diabetes mellitus.
  • insulin which is used for the treatment of diabetes mellitus.
  • insulin can form aggregates and, although this is not of itself disadvantageous, if these undergo chemical modification so that they will not disaggregate in vivo this will have the effect of lowering the physiological activity of the insulin.
  • chemical modification of insulin may result in a product which is recognized by the immune system as foreign with the possibility of the development of an allergic reaction by the patient.
  • the present invention comprises a mixture of a peptide or protein and a hydroxypyridone being:
  • a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen or hydroxy group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, cycloalkoxy, aliphatic ester, halogen or hydroxy group, or a salt thereof;
  • the invention may be applied to the stabilization of the carbon-nitrogen bond of groupings ##STR2## in various peptides and proteins, particularly those having a biological activity of one form or another including animal and plant hormones, for example parathyroid hormone, calcitonin, corticotrophin, cytokines, growth hormones and particularly insulin, hormones controlling the release of other compounds, which compounds are often themselves hormones, for example gonadotrophin releasing hormone, LHRH and LHRH antagonists, immunoglobulins, for example monoclonal antibodies, blood coagulation factors, for example Factor VIII, enzymes and enzyme inhibitors, for example thrombin, as well as fragments of each of these.
  • insulin is used herein to include not only the naturally occurring hormone of various species, for example human, bovine and porcine insulin, but also synthetic versions of the natural hormone and synthetic analogues thereof possessing the hormone activity.
  • peptide and protein stabilization in addition to the stabilization of insulins, other areas of peptide and protein stabilization in which the present invention is particularly applicable include vaccines, i.e. products comprising antigenic materials or antibodies, anti-allergy products in general and particularly the various forms of blood products.
  • vaccines i.e. products comprising antigenic materials or antibodies
  • anti-allergy products in general and particularly the various forms of blood products.
  • blood products include human plasma, fibrinogen, immunoglobulins, blood coagulation factors such as Factor VIII, and thrombin and suffer from similar storage problems to those experienced with the insulins.
  • the invention may be used with hexapeptides and higher peptides or proteins, more especially with decapeptides, and particularly eicosapeptides, and higher peptides or proteins.
  • molecular weight terms the preference is for the use of a peptide or protein with a molecular weight of 500 or 600 daltons or more, for example 1,200 or 2,400 daltons or more.
  • the instability of peptides and proteins is most pronounced where the chain is long enough to undergo folding with consequent interactions between different parts of it, although certain amino acids such as methionine can induce instability even without such folding of the peptide or protein occurring.
  • the materials stabilized may of course contain other groupings than linked amino acid residues, for example glycosyl groups, or may contain other compounds mixed with the peptides and proteins.
  • Hydroxypyridone compounds of types (1), (2) and (3) are described in detail in UK patents GB 2118176B and 2136807B; GB 2146990B; and GB 2146989B, respectively, which relate to the use of such compounds for the removal of toxic amounts of metal from the body, and the various preferred and specific types of compound described in these patents may be used in the present invention. Certain compounds of types (2) and (3) are also described in U.S. Pat. No. 4,698,431.
  • the size of the aliphatic hydrocarbon and alkyl or cycloalkyl moieties in such groups is conveniently in a range of C 1-8 , particularly C 1-6 , for example C 1-4 , such as methyl and ethyl.
  • hydroxypyridones of use in the present invention are discussed in detail in the earlier patents but compounds of particular interest in the context of the present invention are water soluble, neutral compounds of a hydrophilic character.
  • a hydrophilic substituent it is possible to balance the presence of a hydrophilic substituent by the presence of one or more hydrophobic substituents but in order to achieve the appropriate hydrophilic character in the compound it is preferred, for example, that the number of carbon atoms in the aliphatic hydrocarbon, alkoxy and cycloalkoxy moieties and such substituted moieties is limited.
  • the aliphatic hydrocarbon groups are conveniently of 1 to 4 carbon atoms, especially 1 or 2 carbon atoms, when these groups are not themselves substituted.
  • Acyclic rather than cyclic groups are preferred, as are saturated rather than unsaturated groups, the preferred unsubstituted aliphatic hydrocarbon groups and those in the aliphatic amide groups being the alkyl groups ethyl and particularly methyl.
  • the substituted aliphatic hydrocarbon groups are conveniently of 1 to 6 carbon atoms, preferably of 1 to 4 carbon atoms, especially of 1, 2 or 3 carbon atoms.
  • acyclic rather than cyclic, and saturated rather than unsaturated groups are preferred, the preferred substituted aliphatic hydrocarbon groups being substituted methyl, ethyl, isopropyl and n-propyl groups, the three latter alkyl groups conveniently being substituted terminally.
  • Alkoxy groups are preferred to cycloalkoxy groups and the former are conveniently of 1 to 6 carbon atoms, preferably of 1 to 4 carbon atoms and especially of 1 or 2 carbon atoms.
  • Aliphatic amide groups conveniently contain no more than one aliphatic hydrocarbon group which may, for example, be ethyl or especially methyl.
  • substituted aliphatic hydrocarbon group substituents are hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, 2-methoxy-1-methylethyl, ethoxymethyl, 2-ethoxyethyl, 3-ethoxypropyl, and 2-ethoxy-1-methylethyl, the groups in which the oxygen atom is attached to the bonding carbon atom of the group being of less interest in the case of N-substituents in view of the lesser stability of the grouping ##STR3## as compared with ##STR4##
  • a first preferred group of compounds consists of single ring 3-hydroxypyrid-4-ones in which the carbon atoms of the ring each separately are either unsubstituted or are substituted by an aliphatic hydrocarbon group, for example as described above, conveniently at the 6- or particularly at the 2-position, the nitrogen atom being substituted either by an aliphatic hydrocarbon group or by a hydroxy-substituted or particularly an alkoxy-substituted aliphatic hydrocarbon group, for example as described above.
  • a second preferred group of compounds consists of single ring 1-hydroxypyrid-2-ones in which the carbon atoms of the ring are substituted, conveniently at the 6- or 4-position by an alkoxy, alkoxyalkoxy or aliphatic amide substituent.
  • Specific examples of such compounds are 1-hydroxy-4-(2'-methoxyethoxy)-pyrid-2-one, 1-hydroxy-4-(2'-ethoxyethoxy)-pyrid-2-one, and 6-carbamoyl-1-hydroxypyrid-2-one and its 6-(N-methylcarbamoyl) and 6-(N-ethylcarbamoyl) analogues, and salts thereof.
  • a third preferred group of compounds consists of compounds containing three 3-hydroxypyrid-2- or 4-one rings in which the carbon and nitrogen atoms of the rings are either unsubstituted apart from linking groups or are substituted by an aliphatic hydrocarbon group, for example as described above, particularly at the 6-, or especially at the 2-position in the case of the 4-ones.
  • a fourth preferred group consists of compounds containing three 1-hydroxypyrid-2-one rings in which the carbon atoms of the rings are either unsubstituted apart from linking groups or are substituted by an aliphatic hydrocarbon group or an aliphatic amide group, for example as described above, particularly at the 6-or 4-position.
  • Linkage of the rings through the carbon atoms thereof or particularly through the nitrogen atoms thereof for the 3-hydroxypyridones is conveniently effected by linking groups which are of an aliphatic hydrocarbon nature or which additionally contain one or more groups ##STR5##
  • linking groups which are of an aliphatic hydrocarbon nature or which additionally contain one or more groups ##STR5##
  • Specific examples of such compounds are the compound N,N-di-[2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine of Example 8 of GB 2146989B (and compounds 6B, 6C, 9 and 10 listed in Table 4 of that patent.
  • hydroxypyridone compound may be more suited than others for use in particular environments.
  • peptides and proteins may be stored at various pHs, different forms of insulin preparation in particular being stored at both acidic and alkaline pHs.
  • pHs in the range of about 3-5 the 1-hydroxypyrid-2-one compounds, either in single ring or multi-ring form, for example the three ring form, are of particular interest whilst for higher pHs the 3-hydroxypyrid-4-one compounds, either in single ring or multi-ring form, for example the three ring form, are of particular interest.
  • the hydroxypyridones may be prepared by procedures described in the four earlier patents referred to hereinbefore.
  • the C-carbamoyl and -alkylated carbamoyl 1-hydroxypyridones may be prepared as described in U.S. Pat. No. 4,698,431 and the N-alkoxyalkyl and N-hydroxyalkyl 3-hydroxypyrid-4-one compounds may be prepared as described in UK patent GB 2136807B.
  • This latter route involves reaction of a corresponding 3-hydroxy-4-pyrone, or a 3-hydroxy-4-pyrone containing groups convertible to the C-substituents present in the desired hydroxpyridone, with a compound R'NH 2 in which R' represents the group present on the nitrogen atom of the desired compound or a group convertible thereto, the reaction being carried out in the presence of a base, for example an alkali metal hydroxide such as sodium hydroxide.
  • a base for example an alkali metal hydroxide such as sodium hydroxide.
  • the hydroxypyridones may be used in salt form, particularly as a physiologically acceptable salt.
  • salts may be formed between the anion produced by the loss of the hydroxy group proton and a cation such as an alkali metal ion, for example Na + , quaternary ammonium ions or protonated amines such as tris (tris represents 2-amino-2-hydroxymethyl propane 1,3-diol).
  • a cation such as an alkali metal ion, for example Na + , quaternary ammonium ions or protonated amines such as tris (tris represents 2-amino-2-hydroxymethyl propane 1,3-diol).
  • the nitrogen atom of a 3-hydroxypyridone ring may be sufficiently basic, particularly in the case of the 3-hydroxypyrid-4-ones, for salt formation to be effected through reaction with an acid such as hydrochloric acid.
  • the present invention is particularly applicable to the stabilization of peptides and proteins at ambient temperatures or below, for example down to -10° C., especially at 10° C. or less and particularly at 4° C. or less, although it is also of interest for use at about 37° C., especially when using compounds incorporating more than one hydroxypyridone ring, for example the hexadentate three ring compounds.
  • the proportion of hydroxpyridone compound to peptide or protein may vary depending on the nature of the individual materials involved and the conditions to which the stabilized peptide or protein is subjected. However, by way of guidance it may be stated that the use of a ratio by weight of the hydroxypyridone: the peptide or protein of from 0.01:1 to 100:1, particularly from 0.1:1 to 10:1, for example 2:1, is often suitable.
  • more than one hydroxypyridone compound may be used, for example both a single ring bidentate compound and a three ring hexadentate compound, the proportions given then applying to the total of hydroxypyridone compounds.
  • the mixture may consist only of the hydroxypyridone(s) and the peptide or protein but in many other instances the mixture may contain other ingredients, for example diluents particularly in the form of solvents such as water, etc., and/or compounds which further enhance the stability of the peptide or protein.
  • diluents particularly in the form of solvents such as water, etc.
  • compounds which further enhance the stability of the peptide or protein are particularly in the form of solvents such as water, etc., and/or compounds which further enhance the stability of the peptide or protein.
  • a component of potential value in the latter category is zinc which may be provided in the form of various types of zinc-containing compound although these will often be required to be of a physiologically acceptable form and amount.
  • suitable compounds are zinc salts such as zinc chloride, particularly when the peptide protein is in an environment of pH ⁇ 5.0 and zinc hydroxypyridone complexes, particularly when the peptide or protein is in an environment of pH ⁇ 5.0, such complexes conveniently being of a hydroxypyridone as described herein, for example of the same one as is present in metal-free form.
  • Such complexes are further described in U.K. Patent GB 2148896 for the single ring 3-hydroxypyridone compounds and the zinc complexes of the single ring 1-hydroxypyridones and of the multi ring compounds may be prepared in a generally similar fashion.
  • an excess of hydroxypyridone to zinc is used, for example a molar ratio of at least four moles of hydroxypyridone ring to each mole of zinc.
  • the mixture may be in the form of a pharmaceutical composition containing the peptide or protein and hydroxypyridone materials together with a physiologically acceptable diluent or carrier.
  • a pharmaceutical composition containing the peptide or protein and hydroxypyridone materials together with a physiologically acceptable diluent or carrier.
  • the nature of such compositions may be of various forms, many of which are described in the five earlier patents in the context of the formulation of the hydroxypyridones as therapeutic agents.
  • sterile and pyrogen-free aqueous solutions and suspensions for injection are of particular interest.
  • hydroxypyridones are relatively non-toxic compounds and pharmaceutical compositions in which the active component is a peptide or protein stabilized by a hydroxypyridone in a proportion as indicated herein will usually be quite acceptable for direct use.
  • the present invention therefore further includes a pharmaceutical composition which comprises a mixture of a physiologically active peptide or protein and a hydroxypyridone being:
  • a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen or hydroxy group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, cycloalkoxy, aliphatic ester, halogen or hydroxy group, or a salt thereof;
  • composition will generally contain a therapeutically effective amount of the peptide or protein as indicated in the literature as being suitable to produce the desired physiological effect.
  • the hydroxypyridone and peptide or protein components may be mixed in the solid form or in solution depending on the physical nature of the mixture to be stabilized, standard mixing procedures conveniently being applicable. Most usually, however, the final stabilized pharmaceutical composition containing a peptide or protein/hydroxypyridone mixture will be stored in solution form or, to a lesser extent, in freeze dried form. Thus, although it is quite common practice to produce freeze dried preparations of peptides and proteins because of the lack of stability of their solutions, the present invention may enable materials which are normally lyophilised to be produced in solution form owing to the stabilizing effect of the hydroxypyridone compounds.
  • hydroxypyridones may exert another beneficial effect in some circumstances.
  • synthetic and bioengineered peptides and proteins in that these may become contaminated with iron, nickel, zinc and aluminium from HPLC purification procedures.
  • Such metals will bind preferentially to the hydroxypyridones rather than to the peptide or protein in which condition they are more acceptable when the contaminated peptide or protein is administered. It may be appropriate to increase the proportion of hydroxypyridone compound: peptide or protein if a significant amount of such contamination is anticipated.
  • FIGURE is a graph showing the percentage amount of insulin present in various incubated solutions after certain periods of time.
  • insulin bovine, porcine or human-10 units/ml; approximately 10 -4 M
  • a solution was prepared corresponding to that described in Example 1 containing porcine insulin and being pyrogen-free but not sterile.
  • a further solution was prepared in which the hydroxypyridone was replaced by the alternative chelating agent 3-hydroxy-2-methyl-4-pyrone.
  • the solutions were incubated at either 4° C. or 37° C. and the stability of the insulin was studied over a period of 12 weeks through use of the reverse phase HPLC method described by Seipke et al, Angew. Chem. Int. Ed. Engl., 1986, 25, 535-552 and by Grau, Diabetologia, 1985, 28, 458-463.
  • the amount of insulin present in the solution at 4, 8 and 12 weeks was then calculated as a percentage of the original amount present.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
US07/520,203 1989-05-08 1990-05-03 Stabilization of organic compounds Expired - Fee Related US5185319A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8910521 1989-05-08
GB898910521A GB8910521D0 (en) 1989-05-08 1989-05-08 The stabilization of organic compounds

Publications (1)

Publication Number Publication Date
US5185319A true US5185319A (en) 1993-02-09

Family

ID=10656387

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/520,203 Expired - Fee Related US5185319A (en) 1989-05-08 1990-05-03 Stabilization of organic compounds

Country Status (10)

Country Link
US (1) US5185319A (de)
EP (1) EP0397409B1 (de)
JP (1) JPH0320298A (de)
AT (1) ATE91631T1 (de)
CA (1) CA2016165A1 (de)
DE (1) DE69002275T2 (de)
DK (1) DK0397409T3 (de)
ES (1) ES2058797T3 (de)
GB (2) GB8910521D0 (de)
PT (1) PT93974A (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480894A (en) * 1992-08-12 1996-01-02 British Technology Group Limited 3-hydroxypyridin-4-one derivatives as chelating agents
US6294152B1 (en) * 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541116A (en) * 1991-09-30 1996-07-30 B.R.A.H.M.S. Diagnostica Gmbh Method for the stabilization of endogenous, physiologically active peptides
GB9209078D0 (en) * 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822200A (ja) * 1981-08-04 1983-02-09 テイボ−株式会社 極細マ−キングペンのペン先突出量調節機構
EP0093498A2 (de) * 1982-03-24 1983-11-09 National Research Development Corporation Pharmazeutische Zusammensetzungen, die N-substituierte 3-Hydroxypyrid-2-on- oder -4-on-Derivate enthalten
JPS58222007A (ja) * 1982-06-16 1983-12-23 Lion Corp 皮膚用化粧料
JPS59710A (ja) * 1982-06-25 1984-01-05 Matsushita Electric Ind Co Ltd 表示器の制御装置
EP0120669A2 (de) * 1983-03-24 1984-10-03 National Research Development Corporation Hydroxypyridone und ihre pharmazeutischen Zusammensetzungen
EP0138420A2 (de) * 1983-09-23 1985-04-24 National Research Development Corporation 1-Hydroxypyrid-2-on-Derivate enthaltende pharmazeutische Zubereitungen
EP0138421A2 (de) * 1983-09-23 1985-04-24 National Research Development Corporation Hydroxypyridon-Derivate und sie enthaltende pharmazeutische Zubereitungen
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS5822200A (ja) * 1981-08-04 1983-02-09 テイボ−株式会社 極細マ−キングペンのペン先突出量調節機構
EP0093498A2 (de) * 1982-03-24 1983-11-09 National Research Development Corporation Pharmazeutische Zusammensetzungen, die N-substituierte 3-Hydroxypyrid-2-on- oder -4-on-Derivate enthalten
JPS58222007A (ja) * 1982-06-16 1983-12-23 Lion Corp 皮膚用化粧料
JPS59710A (ja) * 1982-06-25 1984-01-05 Matsushita Electric Ind Co Ltd 表示器の制御装置
EP0120669A2 (de) * 1983-03-24 1984-10-03 National Research Development Corporation Hydroxypyridone und ihre pharmazeutischen Zusammensetzungen
EP0138420A2 (de) * 1983-09-23 1985-04-24 National Research Development Corporation 1-Hydroxypyrid-2-on-Derivate enthaltende pharmazeutische Zubereitungen
EP0138421A2 (de) * 1983-09-23 1985-04-24 National Research Development Corporation Hydroxypyridon-Derivate und sie enthaltende pharmazeutische Zubereitungen
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CA vol. 100 (1984) No. 144827f of Devra Japan 59007108. *
Hider et al., "The Effect of Insulin on Free . . . ", Biochem. J., 125, 751-756, (1971).
Hider et al., The Effect of Insulin on Free . . . , Biochem. J., 125, 751 756, (1971). *
Horiki et al., "Neighbouring Group Participation in Peptide Synthesis . . . ", Heterocycles, 1978, 10, pp. 185-198.
Horiki et al., Neighbouring Group Participation in Peptide Synthesis . . . , Heterocycles, 1978, 10, pp. 185 198. *
Kim et al., "2-Pyridon-1-yl Diphenyl Phosphate . . . ", Journal of the Chemical Society, Chemical Communications, 1986, No. 9, p. 719.
Kim et al., 2 Pyridon 1 yl Diphenyl Phosphate . . . , Journal of the Chemical Society, Chemical Communications, 1986, No. 9, p. 719. *
Kontoghiorghes et al. Arzneim ForschDrug Res. 37(11) Nr. 11 (1987) 1099 1102. *
Kontoghiorghes et al. Arzneim-ForschDrug Res. 37(11) Nr. 11 (1987) 1099-1102.
Reynolds (ed), Martindale, 29th Ed. 1989 pp. 1355 1359. *
Reynolds (ed), Martindale, 29th Ed. 1989 pp. 1355-1359.
Windholz (ed), "Butylated Hydroxyanisole . . . ", The Merck Index, 10th edition, 1983, Merck & Co. Inc., Ratway, pp. 1521-1522 & 7764.
Windholz (ed), Butylated Hydroxyanisole . . . , The Merck Index, 10th edition, 1983, Merck & Co. Inc., Ratway, pp. 1521 1522 & 7764. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480894A (en) * 1992-08-12 1996-01-02 British Technology Group Limited 3-hydroxypyridin-4-one derivatives as chelating agents
US6294152B1 (en) * 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone

Also Published As

Publication number Publication date
GB8910521D0 (en) 1989-06-21
CA2016165A1 (en) 1990-11-08
JPH0320298A (ja) 1991-01-29
GB9010086D0 (en) 1990-06-27
ATE91631T1 (de) 1993-08-15
DE69002275T2 (de) 1993-11-04
DE69002275D1 (de) 1993-08-26
EP0397409B1 (de) 1993-07-21
ES2058797T3 (es) 1994-11-01
GB2231331A (en) 1990-11-14
EP0397409A1 (de) 1990-11-14
PT93974A (pt) 1991-01-08
DK0397409T3 (da) 1993-08-30

Similar Documents

Publication Publication Date Title
FI93309B (fi) Menetelmä stabiilin sinkki-protamiini- -interferonikompleksin valmistamiseksi
US4783441A (en) Aqueous protein solutions stable to denaturation
US4885164A (en) Aqueous protein solutions stable to denaturation
KR101176579B1 (ko) 인간 혈청 알부민(ｈｓａ)이 첨가되지 않은 단백질 약제를위한 제제
CA1330301C (en) Stabilised human protein preparations
US4478829A (en) Pharmaceutical preparation containing purified fibronectin
DE60024268T2 (de) Zusammensetzungen mit stabilem faktor viii
US4409233A (en) Highly concentrated preparations of dopa compounds
NZ202856A (en) Stabilised,lyophilised pharmaceutical composition comprising interferon and amino acid
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
JPH05503940A (ja) 新規インスリン組成物
US4866044A (en) Solubilized composition of poorly-soluble pharmaceutical product
CZ108398A3 (cs) Stabilní farmaceutický prostředek
NZ224715A (en) Mixed crystals of insulin and insulin derivatives, pharmaceutical compositions and methods of preparation
SK862004A3 (en) Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
US5185319A (en) Stabilization of organic compounds
DE69322268T2 (de) Stabile zusammensetzung von polypeptiden
Sraer et al. Evidence for glomerular receptors for parathyroid hormone
DE69425581T2 (de) Methode zur stabilisierung von protein c oder aktiviertem protein c und stabilisierte verbindungen
EP0612530A2 (de) Einen für Tumore cytotoxischen Faktor enthaltende pharmazeutische Zusammensetzung
CA1067822A (en) Biologically active amides
DE3942141A1 (de) K2p pro-stabilisierung
CA2005119A1 (en) Use of basic amino acids to solubilize immunoglobulins
CS216160B2 (en) Method of stabilization of the pharmaceutical preparation with contents of salt of alcalic metal with dehydroepiandrosteronsulphate
DE2448530C3 (de) Verfahren zum Herstellen von Derivaten des Diphtherietoxins und diese enthaltende Mittel

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL RESEARCH DEVELOPMENT CORPORATION, A BRITI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:HIDER, ROBERT C.;STOCKHAM, MICHAEL A.;REEL/FRAME:006187/0520

Effective date: 19900605

AS Assignment

Owner name: BRITISH TECHNOLOGY GROUP LIMITED, ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:NATIONAL RESEARCH DEVELOPMENT CORPORATION;REEL/FRAME:006243/0136

Effective date: 19920709

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19970212

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362